BioCytics
Huntersville, US · Delaware corporation
BioCytics conducts translational cancer research, including a project with UNC Charlotte and Carolina BioOncology Institute to study the "dark genome" of cancer cells to identify sequences involved in tumor growth, immune response, and treatment response. Its work spans cell therapy, neoantigens, tumor infiltrating lymphocytes, and clinical research informatics.
BiotechHealthtechMedical Devices
Founders & leadership
JP
John PowderlyPresident & CEO
JP
Jim PowderlyExecutive Officer
MP
Matthew PietrasExecutive Officer
RW
Renaud WarinChief Scientific Officer
Competitors · 8
by search overlapBioAesthetics:81 shared keywords
Built In62 shared keywords
Mapquest52 shared keywordsProvider of geographical information systems and services; acquired by America Online.
智慧芽 (PatSnap)46 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Cowles_Investments_StemCentrx43 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Ziprecruiter42 shared keywords
Diabetes Prevention Program42 shared keywords
BBB41 shared keywords
Companies competing with BioCytics for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$25KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$25KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John PowderlyExecutive Officer, Director
- Jim PowderlyExecutive Officer
- Offering amount
- $7M
- Amount sold
- $25K
- Minimum investment
- $25K
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25KraisedDec 2023 · 1 investors · Other Health CareRule 506(b)
▶$25KraisedDec 2023 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Don L. JacksonExecutive Officer
- Jim PowderlyExecutive Officer
- John PowderlyExecutive Officer, Director
- Stacy PowderlyExecutive Officer
- Offering amount
- $4M
- Amount sold
- $25K
- Minimum investment
- $25K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedMar 2023 · 18 investors · Other Health CareRule 506(b)
▶$1.4MraisedMar 2023 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John PowderlyExecutive Officer, Director
- Matthew PietrasExecutive Officer
- Jim PowderlyExecutive Officer
- Offering amount
- $8M
- Amount sold
- $1.4M
- Minimum investment
- $25K
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.